- Home
- SKYX vs CTNM Comparison
SKYX vs CTNM Comparison
Compare SKYX & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYX
- CTNM
- Stock Information
- Founded
- SKYX 2004
- CTNM 2009
- Country
- SKYX United States
- CTNM United States
- Employees
- SKYX N/A
- CTNM N/A
- Industry
- SKYX Building Products
- CTNM
- Sector
- SKYX Consumer Discretionary
- CTNM
- Exchange
- SKYX Nasdaq
- CTNM Nasdaq
- Market Cap
- SKYX 191.7M
- CTNM 199.3M
- IPO Year
- SKYX 2022
- CTNM 2024
- Fundamental
- Price
- SKYX $1.76
- CTNM $7.59
- Analyst Decision
- SKYX Strong Buy
- CTNM Strong Buy
- Analyst Count
- SKYX 3
- CTNM 4
- Target Price
- SKYX $4.00
- CTNM $29.25
- AVG Volume (30 Days)
- SKYX 647.3K
- CTNM 56.2K
- Earning Date
- SKYX 03-31-2025
- CTNM 03-04-2025
- Dividend Yield
- SKYX N/A
- CTNM N/A
- EPS Growth
- SKYX N/A
- CTNM N/A
- EPS
- SKYX N/A
- CTNM N/A
- Revenue
- SKYX $84,766,991.00
- CTNM N/A
- Revenue This Year
- SKYX $51.65
- CTNM N/A
- Revenue Next Year
- SKYX $33.62
- CTNM N/A
- P/E Ratio
- SKYX N/A
- CTNM N/A
- Revenue Growth
- SKYX 131.47
- CTNM N/A
- 52 Week Low
- SKYX $0.72
- CTNM $7.04
- 52 Week High
- SKYX $2.14
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- SKYX 51.60
- CTNM N/A
- Support Level
- SKYX $1.85
- CTNM N/A
- Resistance Level
- SKYX $2.00
- CTNM N/A
- Average True Range (ATR)
- SKYX 0.19
- CTNM 0.00
- MACD
- SKYX -0.03
- CTNM 0.00
- Stochastic Oscillator
- SKYX 44.44
- CTNM 0.00
About SKYX SKYX Platforms Corp.
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. The company's technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post and is capable of feeding electric power to an appliance. The Company generates its income from the United States.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.